文献速递生殖医学

激光辅助ICSI随机对照试验:卵母细胞存活与胚胎发育

A randomized controlled trial of laser-assisted ICSI.
PubMed 文献 · Hum Reprod · 2020-01-01

STUDY QUESTION: Does the use of a laser to open the zona pellucida during ICSI (laser assisted or LA-ICSI) improve oocyte survival, embryo development and clinical outcomes? SUMMARY ANSWER: Compared to conventional ICSI, LA-ICSI increased rates of oocyte survival and some aspects…

要点

  • LA-ICSI提高卵母细胞存活数(RR 1.08,95%CI 1.05-1.12,P<0.001)。
  • LA-ICSI未改变持续妊娠率(37% vs 42%,OR 0.79,95%CI 0.61-1.03,P=0.09)。
  • 校正卵母细胞存活后,LA-ICSI对可用囊胚无获益(OR 1.01,95%CI 0.95-1.08,P=0.73)。

核心结论

  • LA-ICSI提高卵母细胞存活和部分胚胎发育指标,但未改善持续妊娠率,校正存活后对胚胎利用无益。

主要发现

  • LA-ICSI组存活卵母细胞数更高(RR 1.08,95%CI 1.05-1.12,P<0.001)。
  • LA-ICSI组受精卵数更高(RR 1.08,95%CI 1.04-1.13,P<0.001)。
  • LA-ICSI组可用囊胚数更高(RR 1.09,95%CI 1.04-1.15,P<0.001)。
  • 校正卵母细胞存活后,可用囊胚无组间差异(OR 1.01,95%CI 0.95-1.08,P=0.73)。
  • 持续妊娠率无组间差异:LA-ICSI 179/489(37%) vs ICSI 201/477(42%),OR 0.79,95%CI 0.61-1.03,P=0.09。

关键数值与推荐

  • 主要终点为ICSI后24小时卵母细胞膜完整性存活率,样本量按检测3%存活率提升(99%把握度,1%显著性水平)估算。

临床怎么用

  • LA-ICSI不宜仅基于卵母细胞存活改善而常规用于临床,需先证明其能改善临床结局。

局限性

  • 胚胎学家无法设盲,但随机分配隐藏和结局评估设盲降低了选择与测量偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

STUDY QUESTION: Does the use of a laser to open the zona pellucida during ICSI (laser assisted or LA-ICSI) improve oocyte survival, embryo development and clinical outcomes? SUMMARY ANSWER: Compared to conventional ICSI, LA-ICSI increased rates of oocyte survival and some aspects of embryo development but it did not alter the ongoing pregnancy rate; after adjusting for oocyte survival, there was no beneficial effect of LA-ICSI on embryo development and utilization. WHAT IS KNOWN ALREADY: Oocyte degeneration occurs in a 10th of mature oocytes after ICSI. Pilot studies suggest that LA-ICSI may improve oocyte survivability. STUDY DESIGN, SIZE, DURATION: In a randomized controlled trial, 966 couples (16 122 metaphase II oocytes) were allocated to receive LA-ICSI (intervention) or conventional ICSI (control) between 17 September 2018 and 5 August 2019. Oocyte survival (primary endpoint), embryo development and ongoing pregnancy rates were compared. PARTICIPANTS/MATERIALS, SETTING, METHODS: Couples included in this study were recommended for ICSI due to female or male factor, unexplained infertility or a combination of factors. Patients were ineligible to participate in the study if they had uterine abnormality including thin endometrium, recurrent pregnancy loss, endometriosis or a severe medical condition. Concealed randomization to LA-ICSI or conventional ICSI, allocated in a 1:1 ratio, took place on stimulation Day 1 with replacement of blastocysts on only Day 5. The primary endpoint was oocyte survival with membrane integrity 24 h after the ICSI procedure. The sample size was estimated to detect a 3% increase in oocyte survival after LA-ICSI with 99% power at a 1% significance level. This also permitted the detection of 10% increase in ongoing pregnancy rate after LA-ICSI with 85% power at 5% alpha level. We used Poisson regression with zero-inflation for count data to estimate relative risk (RR) with 95% CI and logistic regression for clinical outcomes to estimate odds ratio (OR) with 95% CI. Both models adjusted for age as a covariate. MAIN RESULTS AND THE ROLE OF CHANCE: Compared with conventional ICSI, LA-ICSI resulted in a higher number of surviving oocytes (RR 1.08, 95% CI 1.05-1.12, P < 0.001), as well as a higher number of fertilized oocytes (RR 1.08, 95% CI 1.04-1.13, P < 0.001) and utilizable blastocysts (RR 1.09, 95% CI 1.04-1.15, P < 0.001). Sensitivity analyses adjusted for oocyte survival showed no between-group difference in utilizable blastocysts (OR 1.01, 95% CI 0.95-1.08, P = 0.73) and by calculating the mean rate, a reduction in utilizable blastocysts was shown (RR 0.95, 95% CI 0.94-0.97, P < 0.001). Ongoing pregnancy showed no between-group difference (LA-ICSI 179/489 (37%) vs ICSI 201/477 (42%), OR 0.79, 95% CI 0.61-1.03, P = 0.09). LIMITATIONS, REASONS FOR CAUTION: It was not possible to blind the embryologists involved in the ICSI procedure. However, there was concealment of randomization and blinding of outcome assessments reducing the risk of selection and measurement bias. WIDER IMPLICATIONS OF THE FINDINGS: A beneficial effect of LA-ICSI on oocyte survival should be shown to improve clinical outcomes, before its use in clinical practice is justified. STUDY FUNDING/COMPETING INTEREST(S): The study received no funding, and the authors declare that there are no conflicts of interest. TRIAL REGISTRATION NUMBER: NCT03665103. TRIAL REGISTRATION DATE: 11 September 2018. DATE OF FIRST PATIENT'S ENROLMENT: 17 September 2018.

来源:Hum Reprod,查看原文。版权归原作者所有。

引用

  1. Fawzy M, Emad M, Mahran A, et al. A randomized controlled trial of laser-assisted ICSI. Hum Reprod. 2020. PMID: 32995832. doi:10.1093/humrep/deaa160

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。